Compare LUMN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUMN | IOVA |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.7B |
| IPO Year | 1994 | 2008 |
| Metric | LUMN | IOVA |
|---|---|---|
| Price | $4.83 | $9.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $7.49 | ★ $14.40 |
| AVG Volume (30 Days) | ★ 13.6M | 10.6M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,402,000,000.00 | N/A |
| Revenue This Year | N/A | $56.63 |
| Revenue Next Year | N/A | $43.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.25 | $1.76 |
| 52 Week High | $11.95 | $15.37 |
| Indicator | LUMN | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 33.05 |
| Support Level | $4.25 | $3.41 |
| Resistance Level | $6.87 | $10.98 |
| Average True Range (ATR) | 0.29 | 0.96 |
| MACD | 0.05 | -0.50 |
| Stochastic Oscillator | 54.85 | 1.66 |
Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017, the 2022 divestiture of much of its local phone business in rural areas, and the 2026 sale of its remaining consumer fiber network to AT&T have shifted the company's operations away from the legacy consumer business and toward enterprise services, which account for about 85%-90% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.